Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study. (2024)

Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study. (1)

Main content 1Search 2Footer 3

+AA-A High contrast

VHL Regional Portal

Information and Knowledge for Health

  • português
  • español
  • english
  • français

Advanced Search EVID@Easy

Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study.

Pompei, Graziella; Campo, Gianluca; Ruggiero, Rossella; Maffeo, Diego; Sgura, Fabio; Arrotti, Salvatore; Preti, Gerlando; Iannaccone, Mario; Erriquez, Andrea; Biscaglia, Simone; Sganzerla, Paolo; Capecchi, Alessandro; Pignatelli, Gianluca; Dall'Ara, Gianni; Saia, Francesco; Tomassini, Francesco; Rolfo, Cristina; Varbella, Ferdinando; Cerrato, Enrico.

Affiliation

  • Pompei G; Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy.
  • Campo G; Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy. Electronic address: cmpglc@unife.it.
  • Ruggiero R; Cardiovascular Department, Infermi Hospital, Rimini, Italy.
  • Maffeo D; Cardiology Unit, Fondazione Poliambulanza Istituto Ospedaliero Brescia, Brescia, Italy.
  • Sgura F; Cardiology Unit, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.
  • Arrotti S; Cardiology Unit, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.
  • Preti G; Interventional Cardiology Unit, AULSS2 Marca Trevigiana, Ospedale di Conegliano, Conegliano, Italy.
  • Iannaccone M; Cardiology Unit, San Giovanni Bosco Hospital, ASL Città di Torino, Turin, Italy.
  • Erriquez A; Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy.
  • Biscaglia S; Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, FE, Italy.
  • Sganzerla P; Interventional Cardiology Unit, IRCCS Istituto Auxologico Italiano, Ospedale San Luca, Milano, Italy.
  • Capecchi A; Cardiology Unit, Maggiore Hospital, Bologna, Italy.
  • Pignatelli G; Cardiology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Dall'Ara G; Cardiology Unit, Morgagni-Pierantoni Hospital, Forlì, Italy.
  • Saia F; Cardiology Unit, St. Orsola Hospital, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Tomassini F; Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, Orbassano, Rivoli Infermi Hospital ASLTO3, Rivoli, Turin, Italy.
  • Rolfo C; Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, Orbassano, Rivoli Infermi Hospital ASLTO3, Rivoli, Turin, Italy.
  • Varbella F; Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, Orbassano, Rivoli Infermi Hospital ASLTO3, Rivoli, Turin, Italy.
  • Cerrato E; Interventional Cardiology Unit, San Luigi Gonzaga University Hospital, Orbassano, Rivoli Infermi Hospital ASLTO3, Rivoli, Turin, Italy.

Int J Cardiol ; 383: 1-7, 2023 07 15.

Article in En

| MEDLINE| ID: mdl-37085121

  • ABSTRACT

ABSTRACT

BACKGROUND:

The resorbable magnesium scaffold (RMS) is a second-generation bioresorbable scaffold (BRS) that has shown conflicting results in previous studies. These findings suggest that patient selection and implantation technique may have an impact on clinical outcomes. This study aimed to investigate the safety and long-term effectiveness of RMS in a narrowly selected population.

METHODS:

SHERPA-MAGIC is an investigator-driven, multicenter, prospective, single-arm study that enrolled patients undergoing BRS coronary implantation in 18 Italian centers. The present analysis considered the first 543 enrolled patients treated with RMS, with a minimum follow-up of 1year. The study protocol included strict criteria for patient selection and standardization of RMS implantation. The primary outcome was the occurrence of the vessel-oriented composite endpoints (VOCE), including cardiac death, target vessel myocardial infarction, and ischemia-driven target vessel revascularization.

RESULTS:

Overall, 635 vessels were treated. The 1-year cumulative occurrence of VOCE was 22 (3.5%, 95% CI 2.2%-5.2%), which was significantly lower than the prespecified estimation (from 5.5% to 8.5%). At the median follow-up of 3.5 [2.6-4.3] years, there were 3 (0.5%) cardiac deaths, 12 (1.9%) target vessel myocardial infarctions, and 33 (5.2%) ischemia-driven target vessel revascularizations. A total of 37 (5.8%, 95%CI 4.1%-7.9%) VOCEs were detected. Scaffold thrombosis occurred in 4 (0.6%, 95%CI 0.1%-1.6%) cases. Patient-level analysis confirmed the findings of the vessel-level analysis.

CONCLUSIONS:

These results confirm the safety and performance of RMS technology. If confirmed in randomized controlled trials, they may rekindle interest in the use of scaffolds in daily practice.

Subject(s)

Drug-Eluting Stents; Myocardial Infarction; Percutaneous Coronary Intervention; Humans; Sirolimus; Magnesium; Prospective Studies; Treatment Outcome; Absorbable Implants; Percutaneous Coronary Intervention/methods; Myocardial Infarction/etiology; Prosthesis Design

Key words

Outcome; Percutaneous coronary intervention; Resorbable magnesium scaffold; Vessel oriented cardiac event

Add to My VHL

Print

XML

PubMed Links

PubMed Links

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug-Eluting Stents / Percutaneous Coronary Intervention / Myocardial Infarction Type of study: Clinical_trials / Etiology_studies / Guideline / Observational_studies Limits: Humans Language: En Journal: Int J Cardiol Year: 2023 Document type: Article Affiliation country: Itália

Add to My VHL

Print

XML

PubMed Links

PubMed Links

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug-Eluting Stents / Percutaneous Coronary Intervention / Myocardial Infarction Type of study: Clinical_trials / Etiology_studies / Guideline / Observational_studies Limits: Humans Language: En Journal: Int J Cardiol Year: 2023 Document type: Article Affiliation country: Itália

Consulta Detalhada

(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))(instance:"regional") AND ( year_cluster:("2002") AND pais_afiliacao:("^iUnited States^eEstados"))

Email
Export
Export format:
RSS

View RSS Add RSS to My VHL

Print

This page Selected references (0)

Long-term outcomes of patients treated with sirolimus-eluting resorbable magnesium scaffolds: Insights from the SHERPA-MAGIC study. (2024)

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Ouida Strosin DO

Last Updated:

Views: 5849

Rating: 4.6 / 5 (56 voted)

Reviews: 87% of readers found this page helpful

Author information

Name: Ouida Strosin DO

Birthday: 1995-04-27

Address: Suite 927 930 Kilback Radial, Candidaville, TN 87795

Phone: +8561498978366

Job: Legacy Manufacturing Specialist

Hobby: Singing, Mountain biking, Water sports, Water sports, Taxidermy, Polo, Pet

Introduction: My name is Ouida Strosin DO, I am a precious, combative, spotless, modern, spotless, beautiful, precious person who loves writing and wants to share my knowledge and understanding with you.